Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

Inclusion Criteria: • Aged 18 years or older, with lymphoid malignancies of B-cell origin as follows: \*Indolent / aggressive B-cell (NHL) Non- Hodgkin's Lymphoma: EXCLUDING: Burkitt lymphoma and precursor B-lymphoblastic leukemia/lymphoma INCLUDING: any non-Hodgkin's B-cell malignancy such as CLL and rare non-Hodgkin's B-cell subtypes such as Hairy Cell Leukemia, Waldenstrom macroglobulinemia, Mantle cell lymphoma, transformed NHL histologies, etc. \*Hodgkin's lymphoma * Life expectancy of 12 weeks or longer. * Subject must have received ≥ 1 prior treatment regimen. * The subject must not be a candidate for potentially curative therapy, including stem cell transplant. Exclusion Criteria: * Received an investigational study drug within 28 days or 5 half-lives (whichever is longer) prior to receiving the first dose of study drug. * Received any approved anticancer medications within 21 days or 5 half-lives (whichever is longer) prior to receiving their first dose of study drug (42 days for nitrosoureas) EXCEPT steroids at ≤ 10 mg prednisone daily (or equivalent). * Has any unresolved toxicity ≥ Grade 2 from previous anticancer therapy. * Has history of brain metastases or spinal cord compression, or lymphoma involving the central nervous system. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≥ 3. * Received allogeneic hematopoietic stem cell transplant within the last 6 months, or has active graft versus host disease (GVHD) following allogeneic transplant, or is currently receiving immunosuppressive therapy following allogeneic transplant. * Received autologous hematopoietic stem cell transplant within the last 3 months. * Laboratory parameters not within the protocol-defined range. * Current or recent history (\<30 days prior to screening and/or \<45 days prior to dosing) of a clinically meaningful bacterial, fungal, parasitic or mycobacterial infection. * Current clinically active viral infection. * Known history of infection with the human immunodeficiency virus (HIV). * History of active hepatitis or positive serology for hepatitis.